Promising combo for aggressive breast cancer hits roadblock: trial stopped early
NCT ID NCT04216472
First seen Nov 01, 2025 · Last updated Jun 15, 2026 · Updated 35 times
Summary
This study tested two drugs, nab-paclitaxel and alpelisib, given before surgery to people with a fast-growing type of breast cancer (triple-negative) that didn't respond to standard chemo. The goal was to shrink tumors before surgery. Only 6 people took part before the study was stopped early, so we don't have clear results on how well it worked.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TRIPLE-NEGATIVE BREAST CARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
M D Anderson Cancer Center
Houston, Texas, 77030, United States
Conditions
Explore the condition pages connected to this study.